PL2970948T3 - Sposoby oczyszczania rna - Google Patents

Sposoby oczyszczania rna

Info

Publication number
PL2970948T3
PL2970948T3 PL14709704T PL14709704T PL2970948T3 PL 2970948 T3 PL2970948 T3 PL 2970948T3 PL 14709704 T PL14709704 T PL 14709704T PL 14709704 T PL14709704 T PL 14709704T PL 2970948 T3 PL2970948 T3 PL 2970948T3
Authority
PL
Poland
Prior art keywords
purification methods
rna purification
rna
methods
purification
Prior art date
Application number
PL14709704T
Other languages
English (en)
Inventor
Francesco Berlanda Scorza
Yingxia Wen
Andrew Geall
Frederick PORTER
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PL2970948T3 publication Critical patent/PL2970948T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Water Supply & Treatment (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
PL14709704T 2013-03-15 2014-03-13 Sposoby oczyszczania rna PL2970948T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799705P 2013-03-15 2013-03-15
EP14709704.2A EP2970948B1 (en) 2013-03-15 2014-03-13 Rna purification methods
PCT/EP2014/055014 WO2014140211A1 (en) 2013-03-15 2014-03-13 Rna purification methods

Publications (1)

Publication Number Publication Date
PL2970948T3 true PL2970948T3 (pl) 2019-06-28

Family

ID=50272650

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14709704T PL2970948T3 (pl) 2013-03-15 2014-03-13 Sposoby oczyszczania rna

Country Status (17)

Country Link
US (3) US11155572B2 (pl)
EP (2) EP2970948B1 (pl)
JP (1) JP6461830B2 (pl)
CN (1) CN105283548A (pl)
BR (1) BR112015023513A2 (pl)
CA (1) CA2906281A1 (pl)
CY (1) CY1121478T1 (pl)
DK (1) DK2970948T3 (pl)
ES (2) ES2923018T3 (pl)
HR (1) HRP20190197T1 (pl)
HU (1) HUE042072T2 (pl)
LT (1) LT2970948T (pl)
PL (1) PL2970948T3 (pl)
PT (1) PT2970948T (pl)
SI (1) SI2970948T1 (pl)
TR (1) TR201903248T4 (pl)
WO (1) WO2014140211A1 (pl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
PL2970948T3 (pl) * 2013-03-15 2019-06-28 Glaxosmithkline Biologicals Sa Sposoby oczyszczania rna
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
DK3303583T3 (da) * 2015-05-29 2020-07-13 Curevac Real Estate Gmbh Fremgangsmåde til fremstilling og oprensning af rna, omfattende mindst et trin til tangential-flow-filtrering
EP3699288A1 (en) 2015-08-07 2020-08-26 CureVac AG Process for the in vivo production of rna in a host cell
US11162880B2 (en) 2015-11-09 2021-11-02 University Of Notre Dame Du Lac Particle size purification method and devices
MX2018007987A (es) 2015-12-28 2019-01-10 Novartis Ag Composiciones y metodos para el tratamiento de hemoglobinopatias.
US12385034B2 (en) 2016-06-24 2025-08-12 Modernatx, Inc. Methods and apparatus for filtration
AU2017299779B2 (en) * 2016-07-21 2021-12-02 Spark Therapeutics, Inc. Scalable high recovery methods for producing high yield recombinant adeno-associated viral (rAAV) vector and recombinant adeno-associated viral (rAAV) vectors produced thereby
WO2018041921A1 (en) 2016-08-31 2018-03-08 Curevac Ag Mixing device for the production of a liquid nucleic acid composition
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
WO2018096179A1 (en) 2016-11-28 2018-05-31 Curevac Ag Method for purifying rna
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
ES2899323T3 (es) 2017-02-27 2022-03-10 Translate Bio Inc Métodos de purificación de ARN mensajero
EP3625363A1 (en) 2017-05-17 2020-03-25 CureVac Real Estate GmbH Method for determining at least one quality parameter of an rna sample
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019030718A1 (en) 2017-08-11 2019-02-14 Glaxosmithkline Biologicals Sa RNA IDENTIFICATION METHOD USING H RNA DIGESTION AND SIZE FRACTIONATION
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. METHODS FOR HPLC ANALYSIS
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11325104B2 (en) * 2017-12-07 2022-05-10 Emp Biotech Gmbh System and method of applied radial technology chromatography
CA3102135A1 (en) * 2018-06-28 2020-01-02 Curevac Ag Bioreactor for rna in vitro transcription
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
ES2957683T3 (es) * 2018-10-24 2024-01-24 Hoffmann La Roche Procedimiento para la purificación de oligonucleótidos
EP3918065A4 (en) * 2019-01-29 2022-10-26 Flagship Pioneering Innovations V, Inc. PROCEDURE FOR SEPARATION OF LONG POLYNUCLEOTIDS FROM A COMPOSITION
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2020165158A1 (en) * 2019-02-11 2020-08-20 Ethris Gmbh Mrna purification by tangential flow filtration
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
US20220306678A1 (en) * 2019-06-20 2022-09-29 Arcturus Therapeutics, Inc. Improved in vitro transcription purification platform
JP7846007B2 (ja) 2019-12-18 2026-04-14 ノバルティス アーゲー 異常ヘモグロビン症の治療用組成物及び方法
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
KR20220156843A (ko) 2020-02-21 2022-11-28 바이오젠 엠에이 인코포레이티드 한외여과 / 정용여과를 사용한 올리고뉴클레오티드 조성물의 제조 방법
US20230265476A1 (en) * 2020-05-12 2023-08-24 Charalampos Makatsoris A method and modular apparatus for the synthesis of rna-based therapeutics
CA3178965A1 (en) 2020-05-15 2021-11-18 Christian COBAUGH Messenger rna encoding cas9 for use in genome-editing systems
CN115715324A (zh) * 2020-06-19 2023-02-24 伊泽阿恩埃免疫疗法股份有限公司 Rna纯化方法
CN111812230A (zh) * 2020-06-24 2020-10-23 南京济群生物科技有限公司 一种半定量测定dna中rna含量的sec-hplc检测方法
CN116367903B (zh) * 2020-09-14 2024-10-25 恩奎斯特技术公司 生物制剂制造及下游纯化工艺技术
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
WO2022240960A1 (en) * 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
WO2022266389A1 (en) * 2021-06-17 2022-12-22 Modernatx, Inc. Alternative rna purification strategies
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
EP4396342A1 (en) 2021-09-01 2024-07-10 GlaxoSmithKline Biologicals S.A. Plasmid dna purification methods
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
AU2023316794A1 (en) 2022-07-29 2025-03-13 Sanofi Pasteur Inc. Methods for ethanol-free mrna purification
EP4594334A2 (en) * 2022-09-28 2025-08-06 ModernaTX, Inc. Purification of nucleotides by means of a mixed-mode purification system
WO2025186218A1 (en) 2024-03-04 2025-09-12 Cytiva Bioprocess R&D Ab Purification and analysis of rna
US20260043018A1 (en) * 2024-08-07 2026-02-12 Arcturus Therapeutics, Inc. Nucleic acid purification
WO2026093528A1 (en) * 2024-10-31 2026-05-07 Etherna Immunotherapies Nv A purification of rna by flowthrough chromatography

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
US6011148A (en) 1996-08-01 2000-01-04 Megabios Corporation Methods for purifying nucleic acids
EP0853123A1 (de) 1997-01-10 1998-07-15 Roche Diagnostics GmbH Reinigung von DNA durch Cross-Flow-Filtration
WO1999040098A1 (de) 1998-02-04 1999-08-12 Merck Patent Gmbh Verfahren zur isolierung und aufreinigung von nucleinsäuren
CA2457565A1 (en) * 2001-10-09 2003-04-17 Genentech, Inc. Novel acidic mammalian proteins and polynucleotides encoding the same
US8075780B2 (en) 2003-11-24 2011-12-13 Millipore Corporation Purification and concentration of synthetic biological molecules
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
WO2008073620A2 (en) * 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US20130189757A1 (en) * 2010-07-16 2013-07-25 Valorisation-Recherche, Limited Partnership Affinity purification of rna under native conditions based on the lambda boxb/n peptide interaction
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
JP2014506873A (ja) 2010-12-10 2014-03-20 トンプソン トレイシー 分離方法のための組成物
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
WO2013103439A1 (en) * 2012-01-06 2013-07-11 Infinity Fuel Cell And Hydrogen, Inc. Electrochemical cell with improved water or gas management
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
PL2970948T3 (pl) * 2013-03-15 2019-06-28 Glaxosmithkline Biologicals Sa Sposoby oczyszczania rna

Also Published As

Publication number Publication date
EP3521429A1 (en) 2019-08-07
EP2970948A1 (en) 2016-01-20
US12018044B2 (en) 2024-06-25
EP2970948B1 (en) 2018-12-26
CY1121478T1 (el) 2020-05-29
DK2970948T3 (en) 2019-04-08
US20160024139A1 (en) 2016-01-28
BR112015023513A2 (pt) 2017-07-18
JP6461830B2 (ja) 2019-01-30
US20240300994A1 (en) 2024-09-12
CA2906281A1 (en) 2014-09-18
JP2016512212A (ja) 2016-04-25
WO2014140211A1 (en) 2014-09-18
HUE042072T2 (hu) 2019-06-28
TR201903248T4 (tr) 2019-03-21
HRP20190197T1 (hr) 2019-04-05
CN105283548A (zh) 2016-01-27
SI2970948T1 (sl) 2019-04-30
ES2720200T3 (es) 2019-07-18
LT2970948T (lt) 2019-03-25
US20210214388A1 (en) 2021-07-15
US11155572B2 (en) 2021-10-26
EP3521429B1 (en) 2022-05-04
PT2970948T (pt) 2019-03-20
ES2923018T3 (es) 2022-09-22

Similar Documents

Publication Publication Date Title
SI2970948T1 (sl) Postopki čiščenja RNA
DK2922554T3 (en) Terminalt modificeret rna
IL240215A0 (en) Methods for the purification of messenger RNA
IL245935A0 (en) Methods for RNA analysis
IL245639A0 (en) water purification
GB201314217D0 (en) Coolant purification
SG11201505198WA (en) Protein purification methods
PL3074342T3 (pl) Sposób oczyszczania kwasu chlorowodorowego
SG11201505204VA (en) Protein purification process
GB201315777D0 (en) Novel method
GB201300957D0 (en) Sequencing method
PL3008082T3 (pl) Sposoby
GB201306980D0 (en) Methods
HUE048326T2 (hu) Béta-hidroxi-béta-metil-vajsav tisztítási módszer
PL2970845T3 (pl) Bioreaktor
GB201209082D0 (en) Purification method
GB201312444D0 (en) Methods
ZA201603797B (en) Novel purification processes
GB201308516D0 (en) Methods
GB201310151D0 (en) Novel method
GB201307327D0 (en) Process
GB201304234D0 (en) Methods
SG11201504596TA (en) Process
GB201303078D0 (en) Methods
GB201314581D0 (en) Purification